PARP1/2 inhibitors yielded encouraging results in combination with immune checkpoint inhibitors by promoting neoantigen release, increasing tumor mutational burden, and enhancing PD-L1 expression (Ding et al., 2019; Lampert et al., 2020). The gene discussed is PARP1; the disease is neoplasm.